Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 AcquisitionLawrence Corey, Myron S. Cohen, Erika Rudnicki et al.|New England Journal of Medicine|2021Cited by 540
Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)Dan H. Barouch, Ludo Lavreys, Frank Tomaka et al.|The Lancet|2018Cited by 342
Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120–MF59 in AdultsGlenda Gray, Lubbe Wiesner, Linda‐Gail Bekker et al.|New England Journal of Medicine|2021Cited by 231
Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 PreventionLindsey R. Baden, Etienne Karita, Gaudensia Mutua et al.|Annals of Internal Medicine|2016Cited by 84
Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trialGlenda Gray, Mookho Malahleha, Kathryn Mngadi et al.|The Lancet Infectious Diseases|2024Cited by 40